References

• 1. Kurdi MS, Jadhav RR, Ratkal, J, Kaur J, Ashwini HR, Hiregouder S, Deva R. The perioperative management of haemophilia: easier said than done. J Haem Pract 2014; 1(3): 7-8.
• 2. Lövdahl S, Henriksson KM, Baghaei F, Holmström M, Nilsson JÅ, Berntorp E, Astermark J. Incidence, mortality rates and causes of deaths in haemophilia patients in Sweden. Haemophilia 2013; 19(3): 362-9. https://doi.org/10.1111/hae.12092.
• 3. Darby SC, Kan SW, Spooner RJ, Giangrande PL, Hill FG, Hay CR, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110(3): 815-25.
• 4. Hermans C, de Moerloose P, Dolan G. Clinical management of older persons with haemophilia. Crit Rev Oncol Hematol 2014; 89(2): 197-206. https://doi.org/10.1016/j.critrevonc.2013.07.005.
• 5. Fischer K, Steen Carlsson K, Petrini P, Holmström M, Ljung R, van den Berg HM, Berntorp E. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood 2013; 122(7): 1129-36. https://doi.org/10.1182/blood-2012-12-470898.
• 6. Viswabandya A, Mathews V, George B, Nair SC, Baidya S, Mammen JJ, Chandy M, Srivastava A. Successful surgical haemostasis in patients with von Willebrand disease with Koate DVI. Haemophilia 2008; 14(4): 763-7. https://doi.org/10.1111/j.1365-2516.2008.01755.x.
• 7. Wu R, Luke KH, Poon MC, Wu X, Zhang N, Zhao L, Su Y, Zhang J. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China. Haemophilia 2011; 17(1): 70-4. https://doi.org/10.1111/j.1365-2516.2010.02348.x.